Ted R Mikuls1, Sindhu R Johnson2, Liana Fraenkel3, Reuben J Arasaratnam4, Lindsey R Baden5, Bonnie L Bermas4, Winn Chatham6, Stanley Cohen7, Karen Costenbader5, Ellen M Gravallese5, Andre C Kalil8, Michael E Weinblatt5, Kevin Winthrop9, Amy S Mudano6, Amy Turner10, Kenneth G Saag6. 1. University of Nebraska Medical Center, Omaha, Nebraska and VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. 2. Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada. 3. Berkshire Health Systems, Pittsfield, Massachusetts, and Yale University, New Haven, Connecticut. 4. University of Texas Southwestern Medical Center, Dallas. 5. Brigham and Women's Hospital, Boston, Massachusetts. 6. University of Alabama at Birmingham. 7. Metroplex Clinical Research Center, Dallas, Texas. 8. University of Nebraska Medical Center, Omaha. 9. Oregon Health and Science University, Portland. 10. American College of Rheumatology, Atlanta, Georgia.
Abstract
OBJECTIVE: To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by e-mail and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus. RESULTS: To date, the task force has approved 80 guidance statements: 36 with moderate and 44 with high consensus. These were combined, resulting in 27 final guidance statements. CONCLUSION: These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
OBJECTIVE: To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by e-mail and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1-9-point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7-9, 4-6, and 1-3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus. RESULTS: To date, the task force has approved 80 guidance statements: 36 with moderate and 44 with high consensus. These were combined, resulting in 27 final guidance statements. CONCLUSION: These guidance statements are provided to promote optimal care during the current pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document," and future updates are anticipated.
Authors: Efstathios Kastritis; George D Kitas; Dimitrios Vassilopoulos; Georgios Giannopoulos; Meletios A Dimopoulos; Petros P Sfikakis Journal: Rheumatol Int Date: 2020-07-11 Impact factor: 2.631
Authors: Raffaella Greco; Tobias Alexander; Joachim Burman; Nicoletta Del Papa; Jeska de Vries-Bouwstra; Dominique Farge; Jörg Henes; Majid Kazmi; Kirill Kirgizov; Paolo A Muraro; Elena Ricart; Montserrat Rovira; Riccardo Saccardi; Basil Sharrack; Emilian Snarski; Barbara Withers; Helen Jessop; Claudia Boglione; Ellen Kramer; Manuela Badoglio; Myriam Labopin; Kim Orchard; Selim Corbacioglu; Per Ljungman; Malgorzata Mikulska; Rafael De la Camara; John A Snowden Journal: Bone Marrow Transplant Date: 2021-05-24 Impact factor: 5.483
Authors: Lai-Shan Tam; Yoshiya Tanaka; Rohini Handa; Zhanguo Li; Jose Paulo Lorenzo; Worawit Louthrenoo; Catherine Hill; Kevin Pile; Philip C Robinson; Leonila F Dans; Li Yang Hsu; Sang-Min Lee; Jiacai Cho; A T M Tanveer Hasan; Babur Salim; Saba Samreen; Syahrul Sazliyana Shaharir; Priscilla Wong; Jeffrey Chau; Debashish Danda; Syed Atiqul Haq Journal: Int J Rheum Dis Date: 2021-05-04 Impact factor: 2.454
Authors: Jonathan S Hausmann; Kevin Kennedy; Julia F Simard; Jean W Liew; Jeffrey A Sparks; Tarin T Moni; Carly Harrison; Maggie J Larché; Mitchell Levine; Sebastian E Sattui; Teresa Semalulu; Gary Foster; Salman Surangiwala; Lehana Thabane; Richard P Beesley; Karen L Durrant; Elsa F Mateus; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Dawn P Richards; David F L Liew; Catherine L Hill; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Emily Sirotich Journal: Lancet Rheumatol Date: 2021-07-22
Authors: Markus A Schramm; Nils Venhoff; Dirk Wagner; Jens Thiel; Daniela Huzly; Nils Craig-Mueller; Marcus Panning; Hartmut Hengel; Winfried V Kern; Reinhard E Voll Journal: Front Immunol Date: 2020-08-28 Impact factor: 7.561